Mucus-bicarbonate Barrier
Mucus-bicarbonate Barrier - Related Videos
05:10
Three-dimensional Quantification of Intestinal Mucus Using Whole-mount Tissue Imaging
0 Views •
2025
This study presents a 3D imaging method using whole-mount intestinal tissues and multi-photon microscopy to quantify secreted mucus, enabling precise volumetric analysis and visualization of mucus dynamics in response to stimuli like carbamoylcholine chloride.
01:29
Roles of Electrolytes: Chloride and Bicarbonate
0 Views •
2024
Chloride ions contribute to the osmotic pressure gradient distinguishing the intracellular fluid (ICF) from the extracellular fluid (ECF). They counterbalance positively charged ions in the ECF and ensure its electrochemical stability. The renal system's process of chloride absorption and release generally mirrors that of sodium ions. Conditions such as hypochloremia can arise from insufficient chloride reabsorption by the kidneys, often compounded by extended bouts of diarrhea, vomiting, or...
01:22
Bicarbonate-Carbonic Acid Buffer
0 Views •
2024
The carbonic acid-bicarbonate buffer system is critical for maintaining the body's pH balance. It operates on the equilibrium: H2CO3 ⇋ H+ + HCO3- In this system, bicarbonate ions (HCO3⁻) act as weak bases, and carbonic acid (H₂CO₃) serves as a weak acid. This dynamic equilibrium enables the system to respond effectively to changes in pH. When hydrogen ion (H+) levels increase, causing a drop in pH, the equilibrium shifts to the left, converting hydrogen ions into carbonic acid. The enzyme...
08:47
Rapid Viscoelastic Characterization of Airway Mucus Using a Benchtop Rheometer
0 Views •
Cited by 5 •
2022
The viscoelastic properties of mucus play a critical role in mucociliary clearance. However, traditional mucus rheological techniques require complex and time-consuming approaches. This study provides a detailed protocol for the use of a benchtop rheometer that can rapidly and reliably perform viscoelastic measurements.
02:04
Generation of a Human Colonoid Monolayer with Barrier Function to Study Host–Pathogen Interactions
0 Views •
2026
Source: In, J. G.,et al. Human Colonoid Monolayers to Study Interactions Between Pathogens, Commensals, and Host Intestinal Epithelium. J. Vis. Exp. (2019).This video demonstrates the procedure for culturing colon-derived epithelial cells on a collagen-coated Transwell system to generate a mucus-producing monolayer that models the intestinal barrier and enables host–pathogen interaction studies.
FAQs
Bicarbonate establishes a near-neutral pH at the epithelial cell surface by buffering hydrogen ions within the mucus gel. This local chemical environment reduces the direct acid challenge faced by gastrointestinal epithelial cells, even when the lumen contains acid. In pharmacology, impaired bicarbonate secretion therefore represents a loss of an important component of mucosal defense and may increase susceptibility to injury.
The two components provide complementary protection. Mucus forms a physical gel that limits the movement of acid and pepsin toward epithelial cells, while bicarbonate neutralizes hydrogen ions that enter the gel. Their combined action creates both a diffusion barrier and a pH-buffering system, so weakening either component can reduce the effectiveness of the overall gastrointestinal defense.
Ulcer risk can increase when protective secretions are weakened, because epithelial cells then face greater exposure to acid, digestive enzymes, and other damaging agents. Reduced buffering or impaired restriction of acid and pepsin diffusion can compromise mucosal integrity. This mechanism helps pharmacologists interpret how drug-related injury may arise when protective defenses no longer adequately counter luminal challenges.
Research evaluates whether a therapy preserves mucosal integrity and reduces gastrointestinal toxicity. The relevant focus is not simply whether luminal acidity changes, but whether the protective mucus and bicarbonate system continues to shield epithelial cells from damaging agents. These outcomes support comparisons among approaches designed to maintain gastric mucosal defense and limit treatment-related injury.
It provides a framework for distinguishing damage caused by luminal challenges from damage associated with weakened protective secretions. When pharmacologists study gastrointestinal toxicity, they can consider whether an agent interferes with the secretions that maintain buffering and restrict acid or pepsin access. This perspective connects drug exposure with changes in mucosal vulnerability and epithelial protection.
The system identifies mucosal defense as a therapeutic target. Development efforts can focus on preserving the secretions that maintain a near-neutral epithelial surface and limit contact with acid and pepsin. Evaluating such strategies is relevant to reducing ulcer formation and gastrointestinal toxicity, particularly when pharmacological agents may weaken normal protective mechanisms.